When appointments are available within a short timeframe, individuals are more likely to address concerns early”— Chad ...

Phase 3 pivotal program initiation for BPL-003 in treatment-resistant depression remains on track for Q2 2026 following successful End-of-Phase 2 meeting with the U.S. Food and Drug AdministrationOn-t ...